A peptide substrate for ATR
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

RAD17-derived Peptide (trifluoroacetate salt)

Item No. 37512

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-alanyl-L-seryl-L-α-glutamyl-L-leucyl-L-prolyl-L-alanyl-L-seryl-L-glutaminyl-L-prolyl-L-glutaminyl-L-prolyl-L-phenylalanyl-L-seryl-L-alanyl-L-lysyl-L-lysyl-L-Lysine, trifluoroacetate salt
Molecular Formula
C81H132N22O25 • XCF3COOH
Formula Weight
1814.1
Purity
≥98%
Formulation (Request formulation change)
A solid
Peptide Sequence
ASELPASQPQPFSAKKK-OH
Solubility(Learn about Variance in Solubility)
Water: soluble
SMILES
[H]N[C@H](C(N[C@@H](CO)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(N1CCC[C@H]1C(N[C@H](C(N[C@@H](CO)C(N[C@@H](CCC(N)=O)C(N2CCC[C@H]2C(N[C@@H](CCC(N)=O)C(N3CCC[C@H]3C(N[C@H](C(N[C@@H](CO)C(N[C@H](C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(O)=O)=O)=O)=O)C)=O)=O)CC4=CC=CC=C4)=O)=O)=O)=O)=O)=O)C)=O)=O)=O)=O)=O)C.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C81H132N22O25.C2HF3O2/c1-43(2)38-55(97-70(116)50(28-31-64(109)110)92-73(119)57(41-105)98-65(111)44(3)85)80(126)103-37-15-23-59(103)75(121)89-46(5)67(113)99-58(42-106)74(120)93-51(26-29-62(86)107)78(124)101-35-16-24-60(101)76(122)94-52(27-30-63(87)108)79(125)102-36-17-25-61(102)77(123)96-54(39-47-18-7-6-8-19-47)71(117)100-56(40-104)72(118)88-45(4)66(112)90-48(20-9-12-32-82)68(114)91-49(21-10-13-33-83)69(115)95-53(81(127)128)22-11-14-34-84;3-2(4,5)1(6)7/h6-8,18-19,43-46,48-61,104-106H,9-17,20-42,82-85H2,1-5H3,(H2,86,107)(H2,87,108)(H,88,118)(H,89,121)(H,90,112)(H,91,114)(H,92,119)(H,93,120)(H,94,122)(H,95,115)(H,96,123)(H,97,116)(H,98,111)(H,99,113)(H,100,117)(H,109,110)(H,127,128);(H,6,7)/t44-,45-,46-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-;/m0./s1
InChi Key
NSLRAWXNLOWIRU-XXOXUGOMSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $31

    Add

    5 mg

    $147

    Add

    10 mg

    $278

    Add

    25 mg

    $616

    Add
    Product Description

    RAD17-derived peptide is a peptide substrate for ataxia-telangiectasia and RAD3-related protein/kinase (ATR).1 It has been used to identify inhibitors of ATR.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Charrier, J.-D., Durrant, S.J., Golec, J.M.C., et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J. Med. Chem. 54(7), 2320-2330 (2011).